Management der akuten myeloischen Leukämie im höheren Alter

Die akute myeloische Leukämie (AML) betrifft vorwiegend Menschen im höheren Lebensalter. Körperliche Grundvoraussetzungen, Präferenzen in der Therapieauswahl sowie die Biologie der Erkrankung verändern sich jedoch mit zunehmendem Alter der Patient*innen. Im Folgenden werden die Herausforderungen im klinischen Management aufgezeigt und aktuelle Ansätze in der Behandlung dieser Patient*innen diskutiert.

Schlüsselwörter

AML - Alter - Myelodysplasie-assoziierte Veränderungen

Publikationsverlauf

Artikel online veröffentlicht:
02. Mai 2025

• Literatur

• 1 Ferrara F, Barosi G, Venditti A. et al. Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy decision making. Leukemia 2013; 27: 997-999
• 2 Apolito V, Arrigo G, Vasseur L. et al. Validation of SIE/SIES/GITMO consensus criteria for unfitness to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax. British Journal of Haematology 2023; 203: e98-e101
• 3 Venditti A, Cairoli R, Caira M. et al. Assessing eligibility for treatment in acute myeloid leukemia in 2023. Expert Review of Hematology 2023; 16: 181-190
• 4 Bellera CA, Rainfray M, Mathoulin-Pélissier S. et al. Screening older cancer patients: first evaluation of the G-8 geriatric screening tool. Annals of Oncology 2012; 23: 2166-2172
• 5 Sorror ML, Storer BE, Fathi AT. et al. Development and Validation of a Novel Acute Myeloid Leukemia–Composite Model to Estimate Risks of Mortality. JAMA Oncology 2017; 3: 1675-1682
• 6 Jahn E, Saadati M, Fenaux P. et al. Clinical impact of the genomic landscape and leukemogenic trajectories in non-intensively treated elderly acute myeloid leukemia patients. Leukemia 2023; 37: 2187-2196
• 7 Tsai XCH, Sun KJ, Lo MY. et al. Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. Blood Cancer J 2023; 13: 1-11
• 8 Lazarevic V, Hörstedt AS, Johansson B. et al. Incidence and prognostic significance of karyotypic subgroups in older patients with acute myeloid leukemia: the Swedish population-based experience. Blood Cancer Journal 2014; 4: e188-e188
• 9 Silva P, Neumann M, Schroeder MP. et al. Acute myeloid leukemia in the elderly is characterized by a distinct genetic and epigenetic landscape. Leukemia 2017; 31: 1640-1644
• 10 Metzeler KH, Herold T, Rothenberg-Thurley M. et al. Spectrum and prognostic relevance of driver gene mutations in acute myeloid leukemia. Blood. American Society of Hematology. Zugriff am 06. November 2024 unter: https://ashpublications.org/blood/article/128/5/686/35562/Spectrum-and-prognostic-relevance-of-driver-gene
• 11 Akute Myeloische Leukämie (AML). Onkopedia. Zugriff am 06. November 2024 unter: https://www.onkopedia.com/de/onkopedia/guidelines/akute-myeloische-leukaemie-aml
• 12 Arber DA, Orazi A, Hasserjian RP. et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood 2022; 140: 1200-1228
• 13 Khoury JD, Solary E, Abla O. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia 2022; 36: 1703-1719
• 14 Huber S, Baer C, Hutter S. et al. AML classification in the year 2023: How to avoid a Babylonian confusion of languages. Leukemia 2023; 37: 1413-1420
• 15 Molica M, Perrone S, Mazzone C. et al. CPX-351: An Old Scheme with a New Formulation in the Treatment of High-Risk AML. Cancers 2022; 14: 2843
• 16 Lancet JE, Uy GL, Newell LF. et al. Five-year final results of a phase III study of CPX-351 versus 7+3 in older adults with newly diagnosed high-risk/secondary AML. Journal of Clinical Oncology. Zugriff am 06. November 2024 unter: https://ascopubs.org/doi/abs/10.1200/JCO.2020.38.15_suppl.7510
• 17 Lindsley RC, Gibson CJ, Murdock HM. et al. Genetic Characteristics and Outcomes By Mutation Status in a Phase 3 Study of CPX-351 Versus 7+3 in Older Adults with Newly Diagnosed, High-Risk/Secondary Acute Myeloid Leukemia (AML). Blood 2019; 134: 15
• 18 Döhner H, Wei AH, Appelbaum FR. et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood 2022; 140: 1345-1377
• 19 Stone RM, Mandrekar Sumithra J, Sanford BL. et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. New England Journal of Medicine 2017; 377: 454-464
• 20 Erba HP, Montesinos P, Kim HJ. et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 2023; 401: 1571-1583
• 21 Döhner H, Weber D, Krzykalla J. et al. Midostaurin plus intensive chemotherapy for younger and older patients with AML and FLT3 internal tandem duplications. Blood Advances 2022; 6: 5345-5355
• 22 Hills RK, Castaigne S, Appelbaum FR. et al. Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. The Lancet Oncology 2014; 15: 986-996
• 23 Richardson PG, Corbacioglu S. Veno-occlusive disease/sinusoidal obstruction syndrome in patients with prior gemtuzumab ozogamicin: literature analysis of survival after defibrotide treatment. Blood Cancer J 2020; 10: 1-5
• 24 Lambert J, Pautas C, Terré C. et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica 2018; 104: 113
• 25 Cortes JE, de Lima M, Dombret H. et al. Prevention, recognition, and management of adverse events associated with gemtuzumab ozogamicin use in acute myeloid leukemia. J Hematol Oncol 2020; 13: 137
• 26 Döhner H, Weber D, Krzykalla J. et al. Intensive chemotherapy with or without gemtuzumab ozogamicin in patients with NPM1-mutated acute myeloid leukaemia (AMLSG 09–09): a randomised, open-label, multicentre, phase 3 trial. The Lancet Haematology 2023; 10: e495-e509
• 27 Wei AH, Döhner H, Pocock C. et al. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. New England Journal of Medicine 2020; 383: 2526-2537
• 28 Burchert A, Bug G, Fritz LV. et al. Sorafenib Maintenance After Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia With FLT3–Internal Tandem Duplication Mutation (SORMAIN). JCO 2020; 38: 2993-3002
• 29 DiNardo CD, Jonas BA, Pullarkat V. et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. New England Journal of Medicine 2020; 383: 617-629
• 30 Fowler-Shorten DJ, Maynard RS, Hampton K. et al. Acute myeloid leukemia-driven IL-3-dependent upregulation of BCL2 in non-malignant hematopoietic stem and progenitor cells increases venetoclax-induced cytopenias. Haematologica 2024; 109: 1576
• 31 Döhner H, Pratz KW, DiNardo CD. et al. ELN Risk Stratification Is Not Predictive of Outcomes for Treatment-Naïve Patients with Acute Myeloid Leukemia Treated with Venetoclax and Azacitidine. Blood 2022; 140: 1441-1444
• 32 Döhner H, DiNardo CD, Appelbaum F. et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood 2024; blood.2024025409
• 33 Pollyea DA, Pratz KW, Wei AH. et al. Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine. Clinical Cancer Research 2022; 28: 5272-5279
• 34 Alber D, Rummelt C, Strüßmann T. et al. Single-Center Experience of Decitabine/Venetoclax in Newly Diagnosed Older AML Patients with Non-Favorable Genetics: Bridging to Allo-HCT or Treatment Continuation. Blood 2023; 142: 7091
• 35 Karrar O, Abdelmagid M, Rana M. et al. Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival. Am J Hematol 2024; 99: E63-E66
• 36 Montesinos P, Recher C, Vives S. et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. New England Journal of Medicine 2022; 386: 1519-1531
• 37 Bhatt A, Powell K, Prasad V. The AGILE trial of ivosidenib plus azacitidine versus azacitidine alone: How many limitations is too many?. Translational Oncology 2022; 25
• 38 Dombret H, Seymour JF, Butrym A. et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 2015; 126: 291-299
• 39 Lübbert M, Wijermans PW, Kicinski M. et al. 10-day decitabine versus 3 + 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 trial. The Lancet Haematology 2023; 10: e879-e889
• 40 Zeidan AM, Fenaux P, Gobbi M. et al. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy. Blood 2022; 140: 285-289
• 41 Garcia-Manero G, McCloskey J, Griffiths EA. et al. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study. The Lancet Haematology 2024; 11: e15-e26